Triple threat: vaccine, immunotherapy, and chemo join forces against HPV-Linked cancer
NCT ID NCT04369937
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This study is for people with a type of head and neck cancer caused by HPV-16 that is considered intermediate risk. The goal is to see if adding an HPV vaccine (ISA101b) and an immunotherapy drug (pembrolizumab) to standard chemoradiation can help keep the cancer from coming back. The trial enrolled 18 participants and is no longer recruiting new patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.